Phase 4
N=65
Assessment of Intercostal Block Scheduling in Preventing Acute Surgical and Post-surgical Pain in Thoracoscopic Surgery
Chest Pain · Surgery
Bottom Line
View on ClinicalTrials.gov: NCT02469610 ↗Enrolled (actual)
65
Serious AEs
1.5%
Results posted
Jul 2019
Primary outcome: Primary: Analgesic Use — 33.35; 35.32 MG
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Intercostal block Bupivacaine based (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Carmel Medical Center
- Primary completion
- Jan 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Analgesic Use |
33.35; 35.32 | — |
| SECONDARY Visual Analog Pain Scale |
3.53; 3.63 | — |
Summary
It is well known that chest surgery patients suffer from high level pain in the perioperative period. The transition to thoracoscopic approaches reduced surgical pain. The proper pain control technique for thoracoscopic approaches is still under debate. One of the most popular methods for pain control is these procedures is the Intercostal block. The Intercostal block is usually based upon topical analgesic. In this study the investigators will try to examine the effect on pain control of the timing of Intercostal block of 100 mg BUPIVACAINE. The study is a prospective comparative study. The cohort will be divided into two groups. In the control group patients will have Intercostal block after surgery and in the study group the intercostal block will be given in the beginning of the surgical procedure. All other analgesic treatment during and post-surgery will be the same in both groups. The study will evaluate pain level in the days after the surgery, analgesic medication consumption and relevant morbidity.
Eligibility Criteria
Inclusion Criteria
- Thoracoscopic surgery candidate.
- Over 18 years old.
- No known allergy to Bupivacaine.
- Patient is able to read understand and singe an inform consent.
Exclusion Criteria
- Previous thoracic operation in the same side.
Data sourced from ClinicalTrials.gov (NCT02469610). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.